• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Does Hormonal Contraceptive Use Lower the Incidence of Severe Asthma Events?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Nwaru et al. (BMJ Thorax, 2020) examined the link between use of hormonal contraceptives and risk of severe asthma exacerbation in reproductive-age women with asthma

METHODS:

  • Retrospective cohort study
  • Data sources
    • Optimum Patient Care Research Database (OPCRD): a population-based longitudinal, anonymized primary care database
    • 630 primary care practices with  >6 million patients
    • 17-year (January 2000 to December 2016) cohort
  • Population
    • Women ages 16 to 45 years old
    • Asthma diagnosis
  • Exposures
    • Hormone contraceptives
  • Study design
    • Data on hormonal contraceptive use, subtype and duration were extracted
    • Severe asthma exacerbation was defined according to recommendations of the European Respiratory Society/American Thoracic Society
      • Asthma-related hospitalization
      • Emergency department visits due to asthma
      • Oral corticosteroid prescriptions
    • Mixed-effects regression analysis used for calculations
  • Goal of study
    • To determine association of hormonal contraceptives with severe asthma exacerbation

RESULTS:

  • 83,084 women with asthma | 456,803 person-years of follow-up time
  • At baseline
    • Women using any hormonal contraceptives: 34%
    • Women using combined (estrogen/progestogen): 25%
    • Women using progestogen only: 9%
  • The following were associated with reduced risk of severe asthma exacerbation vs non-use
    • Previous use of any hormonal contraceptive
      • Incidence rate ratio (IRR) 0.94 (95% CI, 0.92 to 0.97)
    • Current use of any hormonal contraceptive
      • IRR 0.96 (95% CI, 0.94 to 0.98)
    • Previous use of combined hormonal contraceptive
      • IRR 0.92 (95% CI, 0.87 to 0.97)
    • Current use of combined hormonal contraceptive
      • IRR 0.93 (95% CI, 0.91 to 0.96)
    • Longer duration of use of hormonal contraceptives
      • 3 to 4 years
        • IRR 0.94 (95% CI, 0.92 to 0.97)
      • 5+ years
        • IRR 0.91, 95% CI,  0.89 to 0.93

CONCLUSION:

  • Hormonal contraceptive use was associated with reduced incidence of severe asthma events in reproductive-age women
  • The authors had planned to study route of administration (e.g., oral vs intrauterine) but “information was poorly and inconsistently recorded”
  • The authors state that

Further longitudinal studies are required to confirm these findings, as well as mechanistic studies investigating the underlying biological processes through which exogenous sex steroids influence the pathogenesis of asthma in women

Learn More – Primary Sources:

Hormonal contraception and the risk of severe asthma exacerbation: 17-year population-based cohort study

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Does Late Preterm Birth Increase Risk of Asthma?
VDAART RCT Results: Does Vitamin D Supplementation During Pregnancy Reduce Asthma Incidence in Children at 6 Years of Age?
Occupational and House Cleaning: Effects on Lung Function in Women vs Men

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site